The American Academy of Dermatology updated its guidelines on the management of atopic dermatitis and provided new treatment options based on recent evidence.
In this COVID-19 roundup, coverage includes the addition of an Omicron variant component to future vaccine boosters, the relationship between a COVID-19 infection and damage to heart muscle, and how...
The US Food and Drug Administration approved the drug after trials showed a lower rate of relapse in chronic inflammatory demyelinating polyneuropathy or withdrawal for any other reason.
In a phase 3 trial, inebilizumab, a monoclonal antibody targeting CD19+ B cells, reduced flare rates and improved treatment-free and glucocorticoid-free remission in patients with immunoglobulin G4-related...
